Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To obtain estimates of human normal-organ radiation doses of 18F-SKI-249380, as a prerequisite step towards first-in-human trial. 18F-SKI-249380 is a first-of-its-kind PET tracer for imaging the in vivo pharmacokinetics of dasatinib, an investigational targeted therapy for solid malignancies.
Isoflurane-anesthetized mice received tracer dose via tail vein. Organ time-integrated activity coefficients, fractional urinary and hepatobiliary excretion, and total-body clearance kinetics were derived from PET data, with allometric extrapolation to the Standard Man anatomic model and normal-organ-absorbed dose calculations using OLINDA/EXM software.
The human effective dose was 0.031 mSv/MBq. The critical organ was the upper large intestine, with a dose equivalent of 0.25 mSv/MBq. A 190-MBq administered activity of 18F-SKI-249380 is thus predicted to expose an adult human to radiation doses generally comparable to those of routinely used diagnostic radiopharmaceuticals.
Animal-based human dose estimates support first-in-human testing of 18F-SKI-249380.
- Luo FR, Barrett Y, Ji P et al (2006) Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). J Clin Oncol 24(suppl):3046
- U.S. National Institutes of Health (2010). Available at: http://clinicaltrials.gov/. Accessed 11 June 2010.
- Demetri GD, Lo Russo P, MacPherson IRJ et al (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232–6240 CrossRef
- Wang L, Christopher LJ, Cui D et al (2008) Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 36:1828–1839 CrossRef
- Veach DR, Namavari M, Pillarsetty N et al (2007) Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 50:5853–5857 CrossRef
- U.S. Food and Drug Administration (2006). Guidance for industry, investigators, and reviewers: exploratory IND studies.
- Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027
- Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of Nomenclature. J Nucl Med 50:477–484 CrossRef
- Cristy M, Eckerman K (1987). Specific absorbed fractions of energy at various ages from internal photons sources. VII. Adult Male. ORNL/TM-8381. Oak Ridge National Laboratory, Oak Ridge, TN
- U.S. Food and Drug Administration (2009). 21 CFR Part 361. Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research
- Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F (2007) Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8:R255 CrossRef
- Peck CC, Cross JT (2007) Getting the dose right: facts, a blueprint, and encouragements. Clin Pharmacol Ther 82:12–14 CrossRef
- Workman P, Aboagye EO, Chung YL et al (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98:580–598 CrossRef
- Hiwase DK, Saunders V, Hewett D et al (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14:3881–3888 CrossRef
- Luo FR, Yang Z, Camuso A et al (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 12:7180–7186 CrossRef
- Johnson FM, Agrawal S, Burris H et al (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582–1591 CrossRef
- National Cancer Institute U.S. National Institutes of Health (2002). A workshop regarding what in-vivo molecular imaging probes are needed to support future translational studies in cancer therapeutics. Paper presented at: Strategies for Imaging Priority Targets, Frankfurt, Germany
- Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging
Molecular Imaging and Biology
Volume 14, Issue 1 , pp 25-31
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Positron emission tomography
- Dasatinib (substance name)
- Protein-tyrosine kinases [Mesh]
- Molecular imaging
- Industry Sectors
- Author Affiliations
- 1. Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-214B, Box 77, New York, NY, 10065, USA
- 2. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-214B, Box 77, New York, NY, 10065, USA
- 3. Radiochemistry Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 77, Room H-214B, New York, NY, 10065, USA
- 4. Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 77, Room H-214B, New York, NY, 10065, USA
- 5. Program in Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-214B, Box 77, New York, NY, 10065, USA